JW Holdings Corporation (096760.KS)
KRW 3045.0
(0.0%)
KRW 3045.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 301.25 Billion KRW | 0.5% |
| 2022 | 286.61 Billion KRW | 4.05% |
| 2021 | 275.44 Billion KRW | 2.04% |
| 2020 | 269.94 Billion KRW | -4.74% |
| 2019 | 283.39 Billion KRW | 2.45% |
| 2018 | 276.6 Billion KRW | 8.02% |
| 2017 | 256.07 Billion KRW | 7.47% |
| 2016 | 238.27 Billion KRW | 6.82% |
| 2015 | 223.05 Billion KRW | 5.12% |
| 2014 | 212.18 Billion KRW | 5.65% |
| 2013 | 200.83 Billion KRW | 2.63% |
| 2012 | 195.68 Billion KRW | -0.97% |
| 2011 | 197.59 Billion KRW | -3.25% |
| 2010 | 204.24 Billion KRW | -2.07% |
| 2009 | 208.56 Billion KRW | 1.06% |
| 2008 | 206.37 Billion KRW | 116.75% |
| 2007 | 95.21 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 68.07 Billion KRW | 1.88% |
| 2024 Q1 | 66.82 Billion KRW | -9.66% |
| 2023 Q1 | 63.32 Billion KRW | -8.12% |
| 2023 Q3 | -66.68 Billion KRW | 21.57% |
| 2023 FY | 288.04 Billion KRW | 0.5% |
| 2023 Q4 | 73.96 Billion KRW | 210.92% |
| 2023 Q2 | -85.03 Billion KRW | -234.27% |
| 2022 Q4 | 68.92 Billion KRW | -8.4% |
| 2022 Q2 | 74.09 Billion KRW | 8.41% |
| 2022 FY | 286.61 Billion KRW | 4.05% |
| 2022 Q1 | 68.35 Billion KRW | -6.14% |
| 2022 Q3 | 75.24 Billion KRW | 1.54% |
| 2021 Q4 | 72.82 Billion KRW | 25.14% |
| 2021 FY | 275.44 Billion KRW | 2.04% |
| 2021 Q1 | 66.65 Billion KRW | -7.86% |
| 2021 Q2 | 77.77 Billion KRW | 16.69% |
| 2021 Q3 | 58.19 Billion KRW | -25.19% |
| 2020 Q2 | 68.47 Billion KRW | 2.94% |
| 2020 Q1 | 66.52 Billion KRW | -14.69% |
| 2020 FY | 269.94 Billion KRW | -4.74% |
| 2020 Q4 | 72.34 Billion KRW | 15.55% |
| 2020 Q3 | 62.6 Billion KRW | -8.57% |
| 2019 Q4 | 77.97 Billion KRW | 21.4% |
| 2019 Q3 | 64.23 Billion KRW | -10.64% |
| 2019 Q2 | 71.87 Billion KRW | 3.72% |
| 2019 Q1 | 69.3 Billion KRW | -2.03% |
| 2019 FY | 283.39 Billion KRW | 2.45% |
| 2018 Q4 | 70.73 Billion KRW | 4.62% |
| 2018 Q1 | 67.66 Billion KRW | 6.12% |
| 2018 FY | 276.6 Billion KRW | 8.02% |
| 2018 Q2 | 70.59 Billion KRW | 4.32% |
| 2018 Q3 | 67.61 Billion KRW | -4.21% |
| 2017 Q3 | 60.3 Billion KRW | -12.72% |
| 2017 FY | 256.07 Billion KRW | 7.47% |
| 2017 Q4 | 63.76 Billion KRW | 5.74% |
| 2017 Q1 | 62.91 Billion KRW | 4.12% |
| 2017 Q2 | 69.09 Billion KRW | 9.82% |
| 2016 Q1 | 58.68 Billion KRW | 1.63% |
| 2016 Q2 | 59.36 Billion KRW | 1.15% |
| 2016 Q3 | 59.95 Billion KRW | 1.0% |
| 2016 FY | 238.27 Billion KRW | 6.82% |
| 2016 Q4 | 60.42 Billion KRW | 0.79% |
| 2015 FY | 223.05 Billion KRW | 5.12% |
| 2015 Q4 | 57.74 Billion KRW | -0.37% |
| 2015 Q2 | 56 Billion KRW | 9.71% |
| 2015 Q1 | 51.05 Billion KRW | -16.88% |
| 2015 Q3 | 57.95 Billion KRW | 3.48% |
| 2014 Q3 | 51.28 Billion KRW | -1.16% |
| 2014 Q2 | 51.88 Billion KRW | 9.08% |
| 2014 Q1 | 47.56 Billion KRW | -8.28% |
| 2014 FY | 212.18 Billion KRW | 5.65% |
| 2014 Q4 | 61.41 Billion KRW | 19.75% |
| 2013 Q1 | 49.11 Billion KRW | -0.73% |
| 2013 Q3 | 48.36 Billion KRW | -7.56% |
| 2013 Q4 | 51.86 Billion KRW | 7.24% |
| 2013 FY | 200.83 Billion KRW | 2.63% |
| 2013 Q2 | 52.31 Billion KRW | 6.52% |
| 2012 Q4 | 49.47 Billion KRW | 1.51% |
| 2012 Q2 | 51.62 Billion KRW | 11.11% |
| 2012 Q1 | 46.46 Billion KRW | 0.0% |
| 2012 FY | 195.68 Billion KRW | -0.97% |
| 2012 Q3 | 48.73 Billion KRW | -5.6% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 197.59 Billion KRW | -3.25% |
| 2011 Q2 | 11.87 Billion KRW | 167.01% |
| 2011 Q1 | 4.44 Billion KRW | 0.0% |
| 2011 Q3 | 12.02 Billion KRW | 1.28% |
| 2010 Q3 | 4.06 Billion KRW | -17.01% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | 204.24 Billion KRW | -2.07% |
| 2010 Q2 | 4.9 Billion KRW | 27.65% |
| 2010 Q1 | 3.84 Billion KRW | 0.0% |
| 2009 FY | 208.56 Billion KRW | 1.06% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 3.62 Billion KRW | -9.0% |
| 2009 Q2 | 3.97 Billion KRW | 10.6% |
| 2009 Q1 | 3.59 Billion KRW | 0.0% |
| 2008 FY | 206.37 Billion KRW | 116.75% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 3.01 Billion KRW | -3.38% |
| 2008 Q3 | 2.95 Billion KRW | -2.22% |
| 2008 Q1 | 3.12 Billion KRW | 0.0% |
| 2007 FY | 95.21 Billion KRW | 0.0% |
| 2007 Q3 | 2.23 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -537.528% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | -1.096% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | -8.195% |
| HANDOK Inc. | 153.76 Billion KRW | -95.916% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -335.257% |
| Yuhan Corporation | 489.94 Billion KRW | 38.512% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | 1.857% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -620.892% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 50.692% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -318.509% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -72.989% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -652.144% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -222.023% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -162.591% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -537.528% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -609.312% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -301.413% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -413.703% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -15.444% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 26.281% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -26.096% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -135.966% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -341.008% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -358.176% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -72.22% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -537.528% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -20.927% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 46.245% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -26.096% |
| Yuhan Corporation | 489.94 Billion KRW | 38.512% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -55.557% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -333.66% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -437.651% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -26.096% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -138.35% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -154.841% |
| CKD Bio Corp. | 25.19 Billion KRW | -1095.666% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -35.702% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -82.455% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -353.582% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -135.966% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | 14.102% |
| Boryung Corporation | 285.16 Billion KRW | -5.644% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -244.128% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -72.989% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1386.84% |